Orthofuse designs and manufactures next-generation orthopaedic implants using advanced additive manufacturing and novel implant architectures. The company focuses on making procedures more reversible in complex cases, cutting the number of surgical steps while maintaining strong fixation. Its technology is intended to make orthopaedic surgeries safer, more efficient, and to deliver better patient outcomes. Led by CEO and Co-Founder James Scott, Orthofuse is currently refining its product for regulatory approval and early-stage clinical evaluations. The newly raised seed capital will fund further technical development, regulatory readiness, and partnership building. Although still pre-revenue, the company has attracted multiple investor groups, signaling confidence in its approach.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2026